The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

TP53 is the most frequently mutated gene in human cancer and thus an attractive target for novel cancer therapy. Several compounds that can reactive mutant p53 protein have been identified. APR-246 is currently being tested in a phase II clinical trial in high-grade serous ovarian cancer. We have us...

Descripción completa

Detalles Bibliográficos
Autores principales: Synnott, Naoise C., Madden, Stephen F., Bykov, Vladimir J.N., Crown, John, Wiman, Klas G., Duffy, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132178/
https://www.ncbi.nlm.nih.gov/pubmed/30196236
http://dx.doi.org/10.1016/j.tranon.2018.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132178/
https://www.ncbi.nlm.nih.gov/pubmed/30196236
http://dx.doi.org/10.1016/j.tranon.2018.08.009

Ejemplares similares